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What are the novel findings of this work?
In pregnancies with vasa previa, prenatal diagnosis is
associated with a high rate of perinatal survival, whereas
in the absence of prenatal diagnosis, the risk of perinatal
death and hypoxic morbidity in surviving neonates is
increased 25- and 50-fold, respectively. This study high-
lights the importance of prenatal diagnosis in preventing
stillbirth and neonatal death due to vasa previa.
What are the clinical implications of this work?
Prenatal diagnosis of vasa previa is essential for impro-
ving perinatal outcomes associated with this obstetric
complication. Further research should be undertaken to
investigate and incorporate screening for vasa previa into
routine clinical practice.
ABSTRACT
Objectives To derive accurate estimates of perinatal
survival in pregnancies with and without a prenatal
diagnosis of vasa previa based on a systematic review
of the literature and meta-analysis.
Methods A search of MEDLINE, EMBASE and The
Cochrane Library was performed to review relevant cita-
tions reporting on the perinatal outcomes of pregnancies
with vasa previa. We included prospective and retrospec-
tive cohort and population studies that provided data
on pregnancies with a prenatal diagnosis of vasa previa
or cases diagnosed at birth or following postnatal pla-
cental examination. Meta-analysis using a random-effects
model was performed to derive weighted pooled estimates
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of perinatal survival (excluding stillbirths and neonatal
deaths) and intact perinatal survival (additionally exclud-
ing hypoxic morbidity). Incidence rate difference (IRD)
meta-analysis was used to estimate the significance of
differences in pooled proportions between cases of vasa
previa with and those without a prenatal diagnosis. Het-
erogeneity between studies was estimated using Cochran’s
Q and the I2 statistic.
Results We included 21 studies reporting on the perinatal
outcomes of 683 pregnancies with a prenatal diagnosis of
vasa previa. There were three stillbirths (1.01% (95% CI,
0.40–1.87%)), five neonatal deaths (1.19% (95% CI,
0.52–2.12%)) and 675 surviving neonates, resulting in a
pooled estimate for perinatal survival of 98.6% (95% CI,
97.6–99.3%). Based on seven studies that included cases
of vasa previa with and without a prenatal diagnosis,
the pooled perinatal survival in pregnancies without
a prenatal diagnosis (61/118) was 72.1% (95% CI,
50.6–89.4%) vs 98.6% (95% CI, 96.7–99.7%) in cases
with a prenatal diagnosis (224/226). Therefore, the risk
of perinatal death was 25-fold higher when a diagnosis
of vasa previa was not made antenatally, compared
with when it was (odds ratio (OR), 25.39 (95% CI,
7.93–81.31); P < 0.0001). Similarly, the risk of hypoxic
morbidity was increased 50-fold in cases with vasa
previa without a prenatal diagnosis compared with
those with a prenatal diagnosis (36/61 vs 5/224; OR,
50.09 (95% CI, 17.33–144.79)). The intact perinatal
survival rate in cases of vasa previa without a prenatal
diagnosis was significantly lower than in those with a
prenatal diagnosis (28.1% (95% CI, 14.1–44.7%) vs
96.7% (95% CI, 93.6–98.8%)) (IRD, 73.4% (95% CI,
53.9–92.7%); Z = –7.4066, P < 0.001).
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Conclusions Prenatal diagnosis of vasa previa is asso-
ciated with a high rate of perinatal survival, whereas
lack of an antenatal diagnosis significantly increases the
risk of perinatal death and hypoxic morbidity. Further
research should be undertaken to investigate strategies
for incorporating prenatal screening for vasa previa into
routine clinical practice. © 2021 The Authors. Ultrasound
in Obstetrics & Gynecology published by John Wiley &
Sons Ltd on behalf of International Society of Ultrasound
in Obstetrics and Gynecology.
INTRODUCTION
Vasa previa is a condition in which arterial or venous
fetal blood vessels traverse the amniotic membranes in
the lower uterine segment in close proximity to the
internal cervical os, unsupported by placental tissue or
the umbilical cord1–4. Vasa previa can occur either with a
velamentous cord insertion, when fetal vessels traverse
the amniotic membranes from the cord insertion to
the placental tissue, or with a bilobed or succenturiate
placenta, when fetal vessels run freely in the membranes
connecting the placental masses3–5. As these fetal vessels
lie close to the internal cervical os and freely traverse
the amniotic membranes, they can be damaged in the
antenatal or intrapartum period following spontaneous or
iatrogenic rupture of amniotic membranes, thus leading to
severe hypovolemic shock and hemorrhagic fetal death6–8.
Several studies have reported a high rate of live births in
pregnancies with a prenatal diagnosis of vasa previa9–12.
In contrast, there is a high risk of stillbirth, neonatal death
and morbidity in pregnancies with vasa previa without an
antenatal diagnosis8,9,11. A recent large prospective cohort
study examining the effectiveness of a two-stage screening
strategy for vasa previa reported that an accurate prenatal
diagnosis of vasa previa is feasible in routine clinical
practice and is associated with a high rate of live birth13.
The findings of the study suggested that an effective
strategy for the prenatal diagnosis of vasa previa could
potentially contribute to prevention of up to 10% of all
stillbirths13.
The objective of this study was to undertake a system-
atic review of the literature and perform a meta-analysis
to determine accurate estimates of perinatal survival in
pregnancies with and without a prenatal diagnosis of
vasa previa.
METHODS
Data sources and search strategy
This systematic review and meta-analysis was undertaken
based on an a-priori designed study protocol recom-
mended for systematic reviews and meta-analyses14. The
study protocol of the systematic review was registered
in advance with PROSPERO (registration number:
CRD42020125495). An electronic search of MEDLINE,
EMBASE and The Cochrane Library was carried out on
30 March 2020 utilizing combinations of the relevant
medical subject heading (MeSH) terms, keywords and
word variants for ‘vasa previa’, ‘abnormal cord insertion’,
‘velamentous cord’, ‘marginal cord’, ‘bilobed placenta’
and ‘succenturiate lobe’. The search and selection criteria
were restricted to studies in the English language. The
citations retrieved following the electronic search were
examined for relevance to this study based on their
design, sample size, study period and whether they
reported perinatal outcomes of pregnancies with and
without a prenatal diagnosis of vasa previa.
Eligibility and selection criteria for studies
Eligible for inclusion in our study were prospective or
retrospective cohort studies and population-based studies
reporting on the outcomes of pregnancies with vasa previa
that was diagnosed prenatally, at birth or following
postnatal placental examination. Only studies that were
published after the year 2000 were included to ensure that
prenatal diagnosis and perinatal outcomes reflect current
obstetric and neonatal care.
The citations were examined by two reviewers (W.Z.
and S.G.) to produce a list of relevant studies after
exclusion of duplicates, studies that did not fit the
selection criteria after review of the title and abstract,
case reports, letters to the editor, review articles and
conference abstracts. These two authors independently
assessed all the potential studies identified from the
search strategy for inclusion or exclusion and extracted
data using a prespecified template. The reference lists of
relevant articles and reviews were searched manually for
additional reports and any inconsistencies were discussed
with a third reviewer (R.A.) to reach a consensus.
Data extraction and synthesis
For each study included in the systematic review,
information about the following was extracted: authors,
year of enrolment for cases and, if applicable, for
controls, study design, whether the study was single- or
multicenter, whether the study included cases of vasa
previa with or without a prenatal diagnosis, sample size,
rates of stillbirth, neonatal death and hypoxic neonatal
morbidity, defined as 5- or 10-min Apgar score of < 7,
arterial or venous cord pH of < 7 or a need for neonatal
blood transfusion. The primary outcome measure was
perinatal survival, defined as the total number of surviving
neonates after excluding cases of stillbirth or neonatal
death in the first 7 days after birth. The secondary
outcome measure was intact perinatal survival, defined
as the total number of surviving neonates after excluding
stillbirths, neonatal deaths in the 7 days postpartum and
cases with hypoxic neonatal morbidity. Data extracted
for each study were inputted into contingency tables.
Haldane correction was used to account for small event
rates to allow for estimation of variance and pooled
effects. The authors of primary studies were contacted if
further details or clarifications were required.
© 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2021; 57: 710–719.
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Quality assessment
The methodological quality of studies included in the
review was assessed using the Newcastle–Ottawa scale
(NOS), which assesses the quality of non-randomized
studies such as cohort studies with specific regard to three
perspectives: selection of study groups, comparability of
groups and ascertainment of outcome of interest15. Assess-
ment of the domains is performed based on a standardized
checklist and indicators of high quality are awarded a
star. The number and combination of stars expresses the
overall quality of a study compliant with the protocols of
the Agency for Healthcare Research and Quality (good,
fair or poor). The quality of this systematic review and
meta-analysis was validated using PRISMA (preferred
reporting items for systematic reviews and meta-analyses).
The PRISMA statement for this study included a checklist
and a flowchart to allow uniform and transparent
reporting of the systematic review and meta-analysis16.
Meta-analysis and estimation of pooled statistics
Data were extracted from each study to document study
design, sample size and rates of stillbirth, neonatal death
and hypoxic neonatal morbidity. Data were entered
into contingency tables and perinatal survival and intact
survival rates (with 95% CIs) were estimated for each
study weighted by its sample size. Summary statistics
for the outcomes (with 95% CIs) were derived for each
study and were then combined to obtain a pooled
estimate, which was calculated as a weighted average
of the individual study estimates. The pooled summary
statistics were estimated using a random-effects model
(REM), which was chosen for two reasons: firstly, it
allows for assessment of between-study variability in
results by weighting studies using a combination of
their own variance and between-study variance and,
secondly, it provides a pragmatic conservative estimate
of pooled statistics with wider CIs17. Forest plots of
summary statistics for each study were constructed and
final pooled estimates were calculated using data from
the REMs. For studies that included both women with
and those without a prenatal diagnosis of vasa previa,
pooled odds ratios (OR) using REM were calculated for
outcomes with available data. Incidence rate difference
(IRD) meta-analysis using REM was used to estimate the
significance of differences in pooled proportions between
the two groups. The heterogeneity between studies was
estimated using Cochran’s Q heterogeneity statistic and
the I2 statistic. The statistical software package StatsDirect
version 2.7.9 (StatsDirect Ltd, Cheshire, UK) and
MedCalc Statistical Software version 16.4.3 (MedCalc
Software, Ostend, Belgium) were used for data analysis.
RESULTS
Data search results
The electronic search of the databases yielded 1238
potential citations. Of these, we excluded 561 duplicates,
248 citations after review of the title and 384 citations
after review of the abstract. Forty-five manuscripts were
retrieved in full text for detailed assessment and a further
24 studies that did not meet the selection criteria were
excluded; thus, 214,9–13,18–32 studies were included in the
systematic review and meta-analysis. The study selection
process is shown in Figure 1.
Characteristics of included studies
All 21 studies included in the systematic review reported
on the perinatal outcome of pregnancies with vasa
previa. Of these, 144,11,13,22–32 were case series or cohort
studies that reported on perinatal outcome only in
pregnancies with an antenatal diagnosis of vasa previa,
while seven9,10,12,18–21 reported on outcomes in women
with a prenatal diagnosis and those that were diagnosed
incidentally during labor or following postnatal placental
examination. There were three multicenter studies9,12,20
and 18 single-center studies4,10,11,13,18,19,21–32.
Assessment of quality and heterogeneity of studies
The methodological quality of the studies included in this
systematic review was assessed using the NOS. The rating
of the studies based on selection and comparability of
study groups and ascertainment of outcomes of interest is
shown in Table S1. The PRISMA guidance was followed
for reporting this meta-analysis (Table S2).
Stillbirths, neonatal deaths and perinatal survival
in pregnancies with vasa previa
All 21 studies reported on the incidence of stillbirth
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Figure 1 Flowchart showing selection of studies included in
systematic review and meta-analysis.
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with a prenatal diagnosis of vasa previa. There were
three stillbirths (1.01% (95% CI, 0.40–1.87%)) and
five neonatal deaths (1.19% (95% CI, 0.52–2.12%)),
thus adding up to a total of eight perinatal deaths
(1.41% (95% CI, 0.67–2.41%)). Therefore, 675 of the
683 pregnancies resulted in surviving neonates, with
a weighted pooled perinatal survival rate of 98.6%
(95% CI, 97.6–99.3%) (I2 = 0% (95% CI, 0–41.5%))
(Table 1, Figure 2).
Seven studies9,10,12,18–21 reported on the incidence
of stillbirth and neonatal death in both pregnancies
with (n = 226) and those without (n = 118) a prenatal
diagnosis of vasa previa. Amongst the pregnancies with
a prenatal diagnosis, there were two perinatal deaths
(1.39% (95% CI, 0.29–3.29%)), including one stillbirth
(1.11% (95% CI, 0.17–2.86%)) and one neonatal death
(1.11% (95% CI, 0.17–2.86%)). In pregnancies without
a prenatal diagnosis of vasa previa, the stillbirth rate
(32/118; 27.4% (95% CI, 20.0–35.6%)) and neonatal
death rate (25/118; 15.8% (95% CI, 6.98–27.27%))
were significantly higher than in pregnancies with a
prenatal diagnosis (IRD, 24.5% (95% CI, 19.9–66.8%);
Z = 4.9853, P < 0.001 and IRD, 28.6% (95% CI,
13.3–34.0%); Z = 4.4821, P < 0.001, respectively). The
weighted pooled perinatal survival rate in pregnancies
with a prenatal diagnosis of vasa previa (224/226), was
significantly higher than in those without a prenatal
diagnosis (61/118) (98.6% (95% CI, 96.7–99.7%) vs
72.1% (95% CI, 50.6–89.4%); IRD, 43.3% (95% CI,
19.9–66.8%); Z = –3.6134, P < 0.001) (Table 2,
Figure 3). Therefore, the risk of perinatal death was
25-fold higher when a diagnosis of vasa previa was not
made antenatally, compared with when it was (57/118
vs 2/226; pooled OR, 25.39 (95% CI, 7.93–81.31);
P < 0.0001).
Neonatal morbidity and intact perinatal survival
in pregnancies with vasa previa
Of 683 pregnancies with a prenatal diagnosis of vasa
previa, there were 675 surviving neonates. Of these,
12 neonates (12/675; 1.78% (95% CI, 0.92–3.11%))
had features of hypoxic morbidity, thus leaving 663
neonates without any morbidity and resulting in
an intact neonatal survival rate of 97.1% (95% CI,
95.2–98.4%); I2 = 32.1% (95% CI, 0–59.2%) (Table 3,
Figure 4). Similarly, in the seven studies9,10,12,18–21 that
evaluated perinatal outcomes in pregnancies with and
those without a prenatal diagnosis of vasa previa, after
exclusion of stillbirths and neonatal deaths, there were
five neonates (5/224; 2.70% (95% CI, 1.01–5.17%))
with hypoxic morbidity in the prenatal diagnosis
group compared with 36 neonates (36/61; 58.23%
(95% CI, 37.15–77.84%)) in the group without a
prenatal diagnosis (IRD, 57.9% (95% CI, 37.1–78.8%);
Z = 5.4474, P < 0.001). The pooled weighted intact
neonatal survival rate in pregnancies with a prenatal
diagnosis was 96.7% (95% CI, 93.6–98.8%); I2 = 18.4%
(95% CI, 0–65.7%) compared with 28.1% (95% CI,
14.1–44.7%); I2 = 40.0% (95% CI, 0–73.4%) in those
without a prenatal diagnosis of vasa previa (IRD,
73.4% (95% CI, 53.9–92.7%); Z = –7.4066, P < 0.001)
(Table 4, Figure 5). The risk of hypoxic perinatal
morbidity in survivors was increased more than 50-fold
if a prenatal diagnosis of vasa previa was not made
compared to when it was (36/61 vs 5/224; pooled OR,
50.09 (95% CI, 17.33–144.79); P < 0.0001).
DISCUSSION
Principal findings
The findings of this systematic review and meta-analysis
demonstrate that in pregnancies with a prenatal diagnosis
of vasa previa, the total and intact perinatal survival rates
were 99% and 97%, respectively. In contrast, in cases
of vasa previa without a prenatal diagnosis, there was
a significantly increased risk of hypoxic morbidity and
mortality, with correspondingly reduced total and intact
perinatal survival rates of 72% and 28%, respectively.
The impact of prenatal diagnosis on the prevention of
morbidity and mortality from vasa previa is profound,
with a 50-fold increased risk of hypoxic morbidity and
a 25-fold increased risk of perinatal death if a timely
prenatal diagnosis of vasa previa is not made.
Strengths and limitations
The strength of our study is that it summarizes the
results of all relevant contemporary studies published
in the last two decades and provides accurate summary
statistics of the live-birth rate, perinatal survival rate
and intact survival rate in pregnancies with and
without a prenatal diagnosis of vasa previa to highlight
the importance of antenatal screening and prenatal
diagnosis in preventing mortality and morbidity due
to this obstetric complication. This systematic review
and meta-analysis was conducted according to a
standardized methodology, using an a-priori designed
protocol, PROSPERO registration, a comprehensive
search strategy, appropriate quality assessment of the
included studies using the NOS and validation of
the quality of the systematic review using PRISMA.
The limitations of our study relate to standard biases
associated with meta-analyses, such as inclusion of
studies with different sample sizes, methodology and
study design, which may introduce heterogeneity into
the analysis. However, we tried to overcome these
limitations, firstly, by using strict selection criteria,
for example excluding case reports without supporting
clinical information; secondly, by undertaking not only
meta-analysis on all included studies but also nested
analysis on selected studies that were similar in study
design and methodology; and thirdly, by choosing to
use a REM over a fixed-effects model to minimize the
impact of heterogeneity between studies by taking into
account between-study variance, weighting the studies
based on sample size and providing estimates of summary
© 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2021; 57: 710–719.
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Table 1 Meta-analysis to derive aggregate summary statistics of perinatal survival rate from studies reporting on pregnancies with prenatal
diagnosis of vasa previa
Study Total Perinatal survival rate Weight (%)
Lee (2000)22 18 16 (88.9 (65.3–98.6)) 2.70
Catanzarite (2001)4 10 10 (100.0 (69.2–100.0)) 1.56
Francois (2003)18 8 8 (100.0 (63.1–100.0)) 1.28
Oyelese (2004)9 61 59 (96.7 (88.7–99.6)) 8.81
Baulies (2007)23 9 9 (100.0 (66.4–100.0)) 1.42
Smorgick (2010)19 10 10 (100.0 (69.2–100.0)) 1.56
Hagesawa (2010)24 10 10 (100.0 (69.2–100.0)) 1.56
Kanda (2011)10 9 9 (100.0 (66.4–100.0)) 1.42
Rebarber (2014)25 24 24 (100.0 (85.8–100.0)) 3.55
Bronsteen (2013)26 56 53 (94.6 (85.1–98.9)) 8.10
Golic (2013)27 18 18 (100.0 (81.5–100.0)) 2.70
Hasegawa (2015)28 21 21 (100.0 (83.9–100.0)) 3.13
Catanzarite (2016)11 96 96 (100.0 (96.2–100.0)) 13.78
Swank (2016)20 47 47 (100.0 (92.5–100.0)) 6.82
Kulkarni (2018)21 33 33 (100.0 (89.4–100.0)) 4.83
Nohuz (2017)29 8 8 (100.0 (63.1–100.0)) 1.28
Sullivan (2017)12 58 58 (100.0 (93.8–100.0)) 8.38
Melcer (2018)30 38 38 (100.0 (90.7–100.0)) 5.54
Fishel Bartal (2019)31 109 109 (100.0 (96.7–100.0)) 15.63
Yerlikaya-Schatten (2019)32 19 19 (100.0 (82.4–100.0)) 2.84
Zhang (2020)13 21 20 (95.2 (76.2–99.9)) 3.13
Pooled analysis (random effects) 683 675 (98.6 (97.6–99.3)) 100.0
Cochran’s Q (P) 18.1513 (0.5774)
I2 statistic (% (95% CI)) 0 (0–41.5)
Bias (P) –0.3070 (0.0792)
Only first author is given for each study. Data given as n or n (% (95% CI)) unless indicated otherwise.
Pooled estimate 98.6 (97.6–99.3)
Zhang (2020)13 95.2 (76.2–99.9)
Yerlikaya-Schatten (2019)32 100.0 (82.4–100.0)
Fishel Bartal (2019)31 100.0 (96.7–100.0)
Melcer (2018)30 100.0 (90.7–100.0)
Sullivan (2017)12 100.0 (93.8–100.0)
Nohuz (2017)29 100.0 (63.1–100.0)
Kulkarni (2018)21 100.0 (89.4–100.0)
Swank (2016)20 100.0 (92.5–100.0)
Catanzarite (2016)11 100.0 (96.2–100.0)
Hasegawa (2015)28 100.0 (83.9–100.0)
Golic (2013)27 100.0 (81.5–100.0)
Bronsteen (2013)26 94.6 (85.1–98.9)
Rebarber (2014)25 100.0 (85.8–100.0)
Kanda (2011)10 100.0 (66.4–100.0)
Hagesawa (2010)24 100.0 (69.2–100.0)
Smorgick (2010)19 100.0 (69.2–100.0)
Baulies (2007)23 100.0 (66.4–100.0)
Oyelese (2004)9 96.7 (88.7–99.6)
Francois (2003)18 100.0 (63.1–100.0)
Catanzarite (2001)4 100.0 (69.2–100.0)
Lee (2000)22 88.9 (65.3–98.6)
Study % (95% CI)
Perinatal survival (% (95% CI))
50 60 70 80 90 100
Figure 2 Forest plot showing summary statistics for incidence of perinatal survival derived using random-effects model in pregnancies with
prenatal diagnosis of vasa previa. Only first author is given for each study.
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Table 2 Meta-analysis to derive aggregate summary statistics for perinatal survival rate from studies reporting on cases of vasa previa with
prenatal diagnosis and those without prenatal diagnosis of vasa previa
Study Total Perinatal survival rate Weight (%)
Pregnancies with prenatal diagnosis
Francois (2003)18 8 8 (100.0 (63.1–100.0)) 3.86
Oyelese (2004)9 61 59 (96.7 (88.7–99.6)) 26.61
Smorgick (2010)19 10 10 (100.0 (69.2–100.0)) 4.72
Kanda (2011)10 9 9 (100.0 (66.4–100.0)) 4.29
Swank (2016)20 47 47 (100.0 (92.5–100.0)) 20.60
Kulkarni (2018)21 33 33 (100.0 (89.4–100.0)) 14.59
Sullivan (2017)12 58 58 (100.0 (93.8–100.0)) 25.32
Pooled analysis (random effects) 226 224 (98.6 (96.7–99.7)) 100.0
Cochran’s Q (P) 3.1335 (0.7919)
I2 statistic (% (95% CI)) 0 (0–58.8)
Bias (P) –0.1133 (0.7595)
Pregnancies without prenatal diagnosis
Francois (2003)18 5 4 (80.0 (28.4–99.5)) 14.5
Oyelese (2004)9 94 41 (43.6 (33.4–54.2)) 25.7
Smorgick (2010)19 9 8 (88.9 (51.8–99.7)) 17.8
Kanda (2011)10 1 1 (100.0 (2.5–100.0)) 7.5
Swank (2016)20 2 2 (100.0 (15.8–100.0)) 9.9
Kulkarni (2018)21 2 2 (100.0 (15.8–100.0)) 9.9
Sullivan (2017)12 5 3 (60.0 (14.7–94.7)) 14.5
Pooled analysis (random effects) 118 61 (72.1 (50.6–89.4)) 100.0
Cochran’s Q (P) 15.8588 (0.0145)
I2 statistic (% (95% CI)) 62.2 (0–81.4)
Bias (P) 1.8417 (0.0068)
Only first author is given for each study. Data given as n or n (% (95% CI)) unless indicated otherwise.








































Figure 3 Forest plots showing summary statistics for incidence of perinatal survival derived using random-effects model in pregnancies with
vasa previa diagnosed prenatally and those without prenatal diagnosis. Only first author is given for each study.
© 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2021; 57: 710–719.
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Table 3 Meta-analysis to derive aggregate summary statistics of intact perinatal survival rate from studies reporting on pregnancies with
prenatal diagnosis of vasa previa
Study Total Intact survival rate Weight (%)
Lee (2000)22 18 14 (77.8 (52.4–93.6)) 3.61
Catanzarite (2001)4 10 10 (100.0 (69.2–100.0)) 2.30
Francois (2003)18 8 8 (100.0 (63.1–100.0)) 1.93
Oyelese (2004)9 61 57 (93.4 (84.1–98.2)) 7.89
Baulies (2007)23 9 9 (100.0 (66.4–100.0)) 2.12
Smorgick (2010)19 10 10 (100.0 (69.2–100.0)) 2.30
Hagesawa (2010)24 10 10 (100.0 (69.2–100.0)) 2.30
Kanda (2011)10 9 9 (100.0 (66.4–100.0)) 2.12
Rebarber (2014)25 24 24 (100.0 (85.8–100.0)) 4.44
Bronsteen (2013)26 56 53 (94.6 (85.1–98.9)) 7.55
Golic (2013)27 18 18 (100.0 (81.5–100.0)) 3.61
Hasegawa (2015)28 21 21 (100.0 (83.9–100.0)) 4.04
Catanzarite (2016)11 96 96 (100.0 (96.2–100.0)) 9.74
Swank (2016)20 47 47 (100.0 (92.5–100.0)) 6.85
Kulkarni (2018)21 33 33 (100.0 (89.4–100.0)) 5.51
Nohuz (2017)29 8 8 (100.0 (63.1–100.0)) 1.93
Sullivan (2017)12 58 56 (96.6 (88.1–99.6)) 7.69
Melcer (2018)30 38 38 (100.0 (90.7–100.0)) 6.03
Fishel Bartal (2019)31 109 105 (96.3 (90.9–99.0)) 10.24
Yerlikaya–Schatten (2019)32 19 19 (100.0 (82.4–100.0)) 3.76
Zhang (2020)13 21 18 (85.7 (63.7–97.0)) 4.04
Pooled analysis (random effects) 683 663 (97.1 (95.2–98.4)) 100.0
Cochran’s Q (P) 29.4583 (0.0791)
I2 statistic (% (95% CI)) 32.1 (0–59.2)
Bias (P) –0.5253 (0.0838)
Only first author is given for each study. Data given as n or n (% (95% CI)) unless indicated otherwise.
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Bronsteen (2013)26 94.6 (85.1–98.9)
Rebarber (2014)25 100.0 (85.8–100.0)
Kanda (2011)10 100.0 (66.4–100.0)
Hagesawa (2010)24 100.0 (69.2–100.0)
Smorgick (2010)19 100.0 (69.2–100.0)
Baulies (2007)23 100.0 (66.4–100.0)
Oyelese (2004)9 93.4 (84.1–98.2)
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Figure 4 Forest plot showing summary statistics for incidence of intact perinatal survival derived using random-effects model in pregnancies
with prenatal diagnosis of vasa previa. Only first author is given for each study.
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Table 4 Meta-analysis to derive aggregate summary statistics for intact perinatal survival rate from studies reporting on cases of vasa previa
with prenatal diagnosis and those without prenatal diagnosis
Study Total Intact survival rate Weight (%)
Pregnancies with prenatal diagnosis
Francois (2003)18 8 8 (100.0 (63.1–100.0)) 4.8
Oyelese (2004)9 61 57 (93.4 (84.1–98.2)) 24.4
Smorgick (2010)19 10 9 (90.0 (55.5–99.7)) 5.8
Kanda (2011)10 9 9 (100.0 (66.4–100.0)) 5.3
Swank (2016)20 47 47 (100.0 (92.5–100.0)) 20.4
Kulkarni (2018)21 33 33 (100.0 (89.4–100.0)) 15.6
Sullivan (2017)12 58 56 (96.6 (88.1–99.6)) 23.6
Pooled analysis (random effects) 226 219 (96.7 (93.6–98.8)) 100.0
Cochran’s Q (P) 7.3527 (0.2895)
I2 statistic (% (95% CI)) 18.4 (0–65.7)
Bias (P) –0.5944 (0.3766)
Pregnancies without prenatal diagnosis
Francois (2003)18 5 4 (80.0 (28.4–99.5)) 12.9
Oyelese (2004)9 94 17 (18.1 (10.9–27.4)) 35.7
Smorgick (2010)19 9 2 (22.2 (2.8–60.0)) 17.7
Kanda (2011)10 1 0 (0.0 (0.0–97.5)) 5.5
Swank (2016)20 2 1 (50.0 (1.3–98.7)) 7.7
Kulkarni (2018)21 2 0 (0.0 (0.0–84.2)) 7.7
Sullivan (2017)12 5 1 (20.0 (0.5–71.6)) 12.9
Pooled analysis (random effects) 118 25 (28.1 (14.1–44.7)) 100.0
Cochran’s Q (P) 9.9960 (0.1248)
I2 statistic (% (95% CI)) 40 (0–73.4)
Bias (P) 0.6967 (0.4866)
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Figure 5 Forest plots showing summary statistics for incidence of intact perinatal survival derived using random-effects model in pregnancies
with vasa previa diagnosed prenatally and those without prenatal diagnosis. Only first author is given for each study.
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statistics with wider estimates of CIs that are more
clinically generalizable. The adverse perinatal outcomes
reported in the studies included in this systematic review
could also potentially be secondary to causes other than
vasa previa, such as fetal defects, but, given the low
prevalence of these causes, it is unlikely that they affected
the estimates of perinatal survival and 95% CIs reported in
this study.
Implications for clinical practice
The results of our systematic review and meta-analysis
provide unequivocal and clear evidence in favor of
prenatal diagnosis for improving perinatal outcomes
in pregnancies with vasa previa, and highlight and
quantify the impact of a lack of prenatal diagnosis on
stillbirths, hypoxic neonatal morbidity and mortality in
these pregnancies. Our findings are consistent with those
of previous studies that reported that prenatal diagnosis
of vasa previa is associated with a high chance of a
healthy perinatal outcome9–12 compared with absence of
antenatal diagnosis, which is associated with a high risk of
stillbirth and neonatal death8,9,11. In addition to stillbirths
and neonatal deaths, there is also evidence that a lack of
prenatal diagnosis is associated with an increased risk of
emergency Cesarean section as well as hypoxic morbidity
in survivors, as evidenced by poor Apgar scores, low
umbilical cord pH and a need for neonatal transfu-
sion owing to anemia and hemorrhagic shock9,12,21.
Therefore, failure to diagnose vasa previa prenatally is
a considerable risk factor for perinatal morbidity and
mortality.
The findings of this systematic review and meta-analysis
provide a compelling argument in favor of prenatal
diagnosis of vasa previa. It is imperative that further
research be undertaken to investigate potential strategies
to both classify pregnancies at high risk of vasa previa and
identify cases with a confirmed prenatal diagnosis that
could benefit from a structured plan for antenatal mon-
itoring and delivery. A recent prospective study of more
than 25 000 pregnancies examined the effectiveness of a
two-stage screening program for vasa previa and reported
that effective identification of pregnancies at high risk
for vasa previa is feasible in a routine clinical setting and
could lead to accurate prenatal diagnosis of the condition,
which is associated with excellent perinatal outcomes13.
Preventing perinatal death due to undiagnosed vasa
previa in otherwise normal fetuses and neonates should
be an important part of national and international
strategies for the prevention of stillbirths and neonatal
deaths.
Conclusions
Prenatal diagnosis of vasa previa is associated with a
high rate of total and intact perinatal survival, whereas
absence of antenatal diagnosis significantly increases
the risk of perinatal death. Further research should be
undertaken to investigate strategies for incorporating
prenatal screening for vasa previa into routine clinical
practice.
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Resultado perinatal de los embarazos con diagnóst ico prenatal de vasa previa : revis i ón
sistemát ica y metaaná l is is
RESUMEN
Objetivos Obtener estimaciones precisas de la supervivencia perinatal en los embarazos con y sin diagnóstico prenatal
de vasa previa a partir de una revisión sistemática de la literatura y un metaanálisis.
Métodos Se realizó una búsqueda en MEDLINE, EMBASE y The Cochrane Library para revisar los estudios de
las citas pertinentes que informasen sobre los resultados perinatales de embarazos con vasa previa. Se incluyeron
estudios prospectivos y retrospectivos de cohortes y de poblaciones que proporcionaron datos sobre embarazos con
un diagnóstico prenatal de vasa previa, o sobre casos diagnosticados en el momento del nacimiento o tras el examen
postnatal de la placenta. Se realizó un metaanálisis utilizando un modelo de efectos aleatorios para obtener estimaciones
combinadas ponderadas de la supervivencia perinatal (sin incluir el éxitus fetal y las muertes de recién nacidos) y de
la supervivencia perinatal indemne (cuando se excluye además la morbilidad hipóxica). Se utilizó el metaanálisis de
las diferencias en la tasa de incidencia (IRD, por sus siglas en inglés) para estimar la importancia de las diferencias en
las proporciones combinadas entre los casos de vasa previa con y sin diagnóstico prenatal. La heterogeneidad entre
estudios se estimó mediante la prueba Q de Cochran y la prueba estadı́stica I2.
Resultados Se incluyeron 21 estudios que informaron sobre los resultados perinatales de 683 embarazos con un
diagnóstico prenatal de vasa previa. Hubo tres casos de éxitus fetal (1,01% (IC 95%, 0,40–1,87%)), cinco muertes
de recién nacidos (1,19% (IC 95%, 0,52–2,12%)) y 675 recién nacidos supervivientes, lo que dio lugar a una
estimación combinada de la supervivencia perinatal del 98,6% (IC 95%, 97,6–99,3%). En función de los siete estudios
que incluyeron casos de vasa previa con y sin un diagnóstico prenatal, la supervivencia perinatal combinada en los
embarazos sin diagnóstico prenatal (61/118) fue del 72,1% (IC 95%, 50,6–89,4%), en comparación con el 98,6% (IC
95%, 96,7–99,7%) en los casos con diagnóstico prenatal (224/226). Por lo tanto, el riesgo de muerte perinatal fue 25
veces mayor cuando no se diagnosticó vasa previa prenatal, en comparación con cuando sı́ se hizo (razón de momios
[RM], 25,39 (IC 95%, 7,93–81,31); P < 0,0001). De forma similar, el riesgo de morbilidad hipóxica se multiplicó por 50
en los casos con vasa previa sin diagnóstico prenatal, en comparación con los que sı́ que fue diagnosticado (36/61 frente
a 5/224; RM, 50,09 (IC 95%, 17,33–144,79)). La tasa de supervivencia perinatal indemne en los casos de vasa previa
sin un diagnóstico prenatal fue significativamente inferior a la de los casos con un diagnóstico prenatal (28,1% (IC 95%,
14,1–44,7%) frente a 96,7% (IC 95%, 93,6–98,8%)) (IRD, 73,4% (IC 95%, 53,9–92,7%); Z =−7,4066, P < 0,001).
Conclusiones El diagnóstico prenatal de vasa previa se asocia a una alta tasa de supervivencia perinatal, mientras que
la falta de diagnóstico prenatal aumenta significativamente el riesgo de muerte perinatal y de morbilidad hipóxica. Se
deben llevar a cabo más investigaciones para estudiar las estrategias para incorporar la detección prenatal de la vasa
previa en la práctica clı́nica habitual.
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